Nuvectis Pharma (NVCT) Return on Capital Employed (2022 - 2026)
Nuvectis Pharma has reported Return on Capital Employed over the past 5 years, most recently at 162.68% for Q1 2026.
- Quarterly results put Return on Capital Employed at 162.68% for Q1 2026, down 2424.0% from a year ago — trailing twelve months through Mar 2026 was 162.68% (down 2424.0% YoY), and the annual figure for FY2025 was 232.46%, down 3403.0%.
- Return on Capital Employed reached 162.68% in Q1 2026 per NVCT's latest filing, down from 135.49% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 97.75% in Q3 2022 and bottomed at 218.99% in Q4 2024.
- Median Return on Capital Employed over the past 5 years was 141.49% (2023), compared with a mean of 146.66%.
- The largest annual shift saw Return on Capital Employed crashed -5234bps in 2024 before it surged 8350bps in 2025.
- Over 5 years, Return on Capital Employed stood at 116.93% in 2022, then crashed by -43bps to 166.65% in 2023, then crashed by -31bps to 218.99% in 2024, then soared by 38bps to 135.49% in 2025, then decreased by -20bps to 162.68% in 2026.
- Business Quant data shows Return on Capital Employed for NVCT at 162.68% in Q1 2026, 135.49% in Q4 2025, and 133.9% in Q3 2025.